抗体药物偶联物在肺癌中的应用:近期进展与实施策略
本文综述了抗体药物偶联物(ADC)在肺癌治疗中的可用证据与未来前景,涵盖基于结构的药物设计、作用机制和耐药概念。主要靶点包括HER2、HER3、Trop-2、c-MET、CEACAM5和B7-H3,在非小细胞肺癌中的结果较SCLC更受鼓舞。多种ADC正单药或联合化疗/免疫检查点抑制剂进行评估,患者选择策略及生物标志物理解仍在演进。
要点
- ADC主要靶点为肺癌细胞常表达而正常组织不表达的抗原,包括HER2、HER3、Trop-2、c-MET、CEACAM5和B7-H3。
- 多种ADC在肺癌领域显示鼓舞性结果,非小细胞肺癌较SCLC组织学更多。
- ADC正单药或联合化疗/免疫检查点抑制剂评估,最佳患者选择策略仍在演进。
核心结论
- ADC是增长最快的肿瘤治疗之一,融合细胞毒payload与靶向癌细胞膜抗原的单克隆抗体的高特异性和选择性。
- 多种ADC在肺癌中显示鼓舞性结果,NSCLC较SCLC更多,最佳患者选择策略仍在演进。
研究设计与样本
- 综述,讨论ADC治疗肺癌的可用证据与未来前景,包括基于结构的药物设计、作用机制和耐药概念。
- 数据按特定靶抗原、生物学、疗效和安全性总结,ADC间因payload及药代/药效学特性而异。
主要发现
- 主要靶抗原有HER2、HER3、Trop-2、c-MET、CEACAM5和B7-H3,每个有一个或多个特异性ADC在肺癌领域显示鼓舞性结果。
- ADC结果在NSCLC较SCLC组织学更多。
- 多种ADC正单药或联合不同分子(如化疗药或免疫检查点抑制剂)评估。
- 患者选择策略演进,包括生物标志物理解改善,涉及payload耐药或应答标志物及抗体靶点。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibody-drug conjugates (ADCs) are one of the fastest-growing oncology therapeutics, merging the cytotoxic effect of conjugated payload with the high specific ability and selectivity of monoclonal antibody targeted on a specific cancer cell membrane antigen. The main targets for ADC development are antigens commonly expressed by lung cancer cells, but not in normal tissues. They include human epidermal growth factor receptor 2, human epidermal growth factor receptor 3, trophoblast cell surface antigen 2, c-MET, carcinoembryonic antigen-related cell adhesion molecule 5, and B7-H3, each with one or more specific ADCs that showed encouraging results in the lung cancer field, more in non-small-cell lung cancer than in small-cell lung cancer histology. To date, multiple ADCs are under evaluation, alone or in combination with different molecules (eg, chemotherapy agents or immune checkpoint inhibitors), and the optimal strategy for selecting patients who may benefit from the treatment is evolving, including an improvement of biomarker understanding, involving markers of resistance or response to the payload, besides the antibody target. In this review, we discuss the available evidence and future perspectives on ADCs for lung cancer treatment, including a comprehensive discussion on structure-based drug design, mechanism of action, and resistance concepts. Data were summarized by specific target antigen, biology, efficacy, and safety, differing among ADCs according to the ADC payload and their pharmacokinetics and pharmacodynamics properties.
引用
- Passaro A, Jänne PA, Peters S, et al. Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies. J Clin Oncol. 2023. PMID: 37224424. doi:10.1200/JCO.23.00013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。